How many clinical trials does AbbVie have on ClinicalTrials.gov?

AbbVie is listed as the lead sponsor on 1,161 clinical trials in ClinicalTrials.gov, 248 of which are currently active (recruiting, enrolling, or ongoing).

How many of AbbVie's trials are in Phase 3?

318 of AbbVie's trials are in Phase 3, spread across 165 active drug programs.

What therapeutic areas does AbbVie focus on?

AbbVie's most-studied conditions on ClinicalTrials.gov are Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Healthy Volunteer, Healthy Volunteers.

When are AbbVie's next clinical trial readouts?

AbbVie has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate”, expected around 2017-10-27.

Clinical Trials Radar

Built by the team at ForesightIQ

ClinicalTrials.gov

All sponsors

AbbVie

abbvie.com

Total trials

1,161

Active

248

Phase 3

318

Total enrollment

416,870

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 40 of 165 active programs · click any cell for trials

Active only

Intervention	Early Phase 1	Phase 1	Phase 2	Phase 4	N/A	Total
Venetoclax	—					56
Azacitidine	—				—	13
Upadacitinib	—					55
Risankizumab	—					57
Telisotuzumab Adizutecan	—			—		13
Budigalimab	—			—	—	15
Bevacizumab	—			—	—	15
Carboplatin	—			—	—	28
Dexamethasone	—			—	—	24
Lutikizumab	—	—		—	—	8
Etentamig	—			—	—	7
Atogepant	—		—			12
Daratumumab	—			—	—	7
Livmoniplimab	—			—	—	6
Cisplatin	—			—	—	7
Pomalidomide	—			—	—	7
Fluorouracil	—	—		—	—	6
Lenalidomide	—			—	—	6
Adalimumab	—					65
Telisotuzumab Vedotin	—			—		7
Ubrogepant	—		—		—	6
Pemetrexed	—			—	—	7
Ruxolitinib	—			—	—	6
Docetaxel	—			—	—	5
Obinutuzumab	—			—	—	5
Oxaliplatin	—	—		—	—	4
Standard of Care	—	—		—	—	4
Osimertinib	—		—	—	—	4
Carfilzomib	—			—	—	4
Topical Steroid	—	—		—	—	3
ABBV-RGX-314 Dose 1	—	—		—	—	3
ABBV-RGX-314 Dose 2	—	—		—	—	3
Navitoclax	—			—		10
ABBV-706	—			—		4
risankizumab SC	—	—		—	—	6
Bortezomib	—			—	—	5
Irinotecan	—			—	—	4
Pembrolizumab	—			—	—	3
Pivekimab Sunirine	—		—	—	—	2
Surabgene Lomparvovec	—	—	—	—	—	2

125 more active programs hidden

Next readouts

2017-10-27
2020-06-22
2020-10-08
2021-02-16
2023-09-06
2024-02-07
2025-01-29
2025-04-28
2025-07-07
2025-09-23

Top conditions

Rheumatoid Arthritis56
Psoriasis48
Crohn's Disease44
Healthy Volunteer36
Healthy Volunteers36
Chronic Hepatitis C35
Psoriatic Arthritis27
Ulcerative Colitis26

Frequently asked questions about AbbVie

How many clinical trials does AbbVie have on ClinicalTrials.gov?: AbbVie is listed as the lead sponsor on 1,161 clinical trials in ClinicalTrials.gov, 248 of which are currently active (recruiting, enrolling, or ongoing).
How many of AbbVie's trials are in Phase 3?: 318 of AbbVie's trials are in Phase 3, spread across 165 active drug programs.
What therapeutic areas does AbbVie focus on?: AbbVie's most-studied conditions on ClinicalTrials.gov are Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Healthy Volunteer, Healthy Volunteers.
When are AbbVie's next clinical trial readouts?: AbbVie has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate”, expected around 2017-10-27.